Russell Glass, Headspace CEO
January 25, 2024 09:48 AM ESTUpdated 10:52 AM
Health Tech

Head­space plans to be cash-flow pos­i­tive in the first quar­ter of 2024

Lydia Ramsey Pflanzer

Deputy Editor

(This sto­ry is from our new Health Tech newslet­ter. If you’d like to sign up, just click here.)

SAN FRAN­CIS­CO � …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

‭ Regulatory Lead / Head of Regulatory‬

Autonomy Bio Inc.

San Francisco, CA 94107, USA

TRENDING NOW

Chi­na’s biotech mar­ket is stag­ing a come­back that US biotech can on­ly wish for

Large vac­cine mak­ers stand by their in­vest­ments de­spite US head­winds

With aims to be­come a 'gen­er­a­tional biotech,' Zealand Phar­ma hires Lil­ly vet­er­an as sci­ence chief

Makary, in one of first com­ments on FDA pol­i­cy, floats new path­way for rare dis­ease drugs

Genen­tech vet launch­es ADC start­up with $20M

sponsored

AD­STI­LADRIN® (nad­o­fara­gene fi­rade­n­ovec-vncg) – A Grow­ing Body of Clin­i­cal Da­ta and Re­al-World Ev­i­dence

A service from the Financial Times